Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human C-MYC Antibodies:
anti-Rat (Rattus) C-MYC Antibodies:
anti-Mouse (Murine) C-MYC Antibodies:
Go to our pre-filtered search.
Human Monoclonal C-MYC Primary Antibody for FACS, IHC (p) - ABIN302017
Veracini, Simon, Richard, Schraven, Horejsi, Roche, Benistant: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. in The Journal of cell biology 2008
Show all 15 Pubmed References
Human Monoclonal C-MYC Primary Antibody for FACS, IHC (p) - ABIN302092
Wang, Campoli, Ko, Luo, Ferrone: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. in Journal of immunological methods 2004
Show all 14 Pubmed References
All Species Monoclonal C-MYC Primary Antibody for FACS, IP - ABIN2749043
Persson, Hennighausen, Taub, DeGrado, Leder: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. in Science (New York, N.Y.) 1984
Show all 15 Pubmed References
Chicken Monoclonal C-MYC Primary Antibody for ChIP, CyTOF - ABIN152253
Locker, Dowle, Ellis, Elston, Blamey, Sikora, Evan, Robins: c-myc oncogene product expression and prognosis in operable breast cancer. in British journal of cancer 1989
Show all 10 Pubmed References
Human Polyclonal C-MYC Primary Antibody for ELISA, ICC - ABIN6263457
Tang, Peng, Huang, Xie, Chen, Shen, Gao, You, Xie, Chen: Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer. in Current cancer drug targets 2018
Show all 4 Pubmed References
Human Monoclonal C-MYC Primary Antibody for IF, IHC (p) - ABIN533219
Huang, Bredemeyer, Walker, Bassing, Sleckman: Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. in European journal of immunology 2008
Show all 3 Pubmed References
Human Monoclonal C-MYC Primary Antibody for FACS, IHC (p) - ABIN536092
Fujiwara, Poikonen, Aleman, Valtavaara, Saksela, Mayer: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. in Biochemistry 2002
Show all 3 Pubmed References
Human Monoclonal C-MYC Primary Antibody for IHC (fro), IF - ABIN2477762
Quant, Woo: Normal values of eye position in the Chinese population of Hong Kong. in Optometry and vision science : official publication of the American Academy of Optometry 1992
Show all 4 Pubmed References
Human Monoclonal C-MYC Primary Antibody for IF, WB - ABIN3201011
Khanna, Böckelman, Hemmes, Junttila, Wiksten, Lundin, Junnila, Murphy, Evan, Haglund, Westermarck, Ristimäki: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. in Journal of the National Cancer Institute 2009
Show all 2 Pubmed References
MYC amplification and MYC overexpression occurred almost exclusively in secondary cutaneous angiosarcoma in our series.
High c-myc expression is associated with the development of prostate cancer.
Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121 (show ZNF121 Antibodies)-dependent MYC expression by sequestering miR (show MLXIP Antibodies)-4302.
Authors conclude that quantitative measurements of intratumor heterogeneity by multiplex FISH, detection of MYC amplification and TP53 (show TP53 Antibodies) mutation could augment prognostication in breast cancer patients.
PCYT1A (show PCYT1A Antibodies) was upregulated by MYC, which resulted in the induction of aberrant choline metabolism and the inhibition of B-lymphoma cell necroptosis.
Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 (show BCL6 Antibodies) linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas.
CD30 (show TNFRSF8 Antibodies)+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 (show BCL2 Antibodies) protein expression.
High MYC amplification is associated with HER2 (show ERBB2 Antibodies) positive breast cancers in African American women.
These data suggest that MYC acts as a master coordinator that inversely modulates the impact of cell cycle and circadian clock on gene expression via its interaction with MIZ1 (show ZBTB17 Antibodies).
In our study, the c-myc oncogene (show RAB1A Antibodies) was amplified in 11.1% of BPH (show GLI3 Antibodies) samples. Bivariate analysis failed to reveal any significant association between oncogene (show RAB1A Antibodies) amplification and the clinicopathologic variables examined.
Ouabain-induced proliferation might be attributed, at least in part, to decrease of intracellular free calcium and increase of c-myc mRNA expression, and that may be directly or indirectly involved in regulation of blood pressure.
report the isolation of complete coding regions of rabbit SOX2, KLF4, C-MYC and NANOG, which encode transcription factors that play crucial regulatory roles during early mammalian embryonic development
MYC binding is enriched at neuroendocrine genes in tumor cells and loss of MYC reduces ductal-neuroendocrine lineage heterogeneity, while deregulated MYC expression in KRAS mutants increases this phenotype.
Although either BCR (show BCR Antibodies) or CD40 (show CD40 Antibodies) ligation induced c-Myc in naive B cells, both signals were required to highly induce c-Myc, a critical mediator of GC B (show NPR2 Antibodies) cell survival and cell cycle reentry.
Myc is a component that links neuromesodermal progenitors maintenance and pre-somitic mesoderm maturation during the body axis elongation stages of mouse embryogenesis.
Myc potentiates the Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signalling pathway, which cooperates with the transcriptional regulatory network in sustaining embryonic stem cell self-renewal.
Although mnt heterozygosity clearly slowed lymphomagenesis in vavP-MYC10 and Emu-myc mice, the change(s) in cellular properties responsible for this effect remain to be identified.
clusters of enhancers, such as BENC in the myc gene, form highly combinatorial systems that allow precise control of gene expression across normal cellular hierarchies and which also can be hijacked in malignancies
Conditional deletion of Myc in hyaloid vascular endothelial cells suppressed both proliferation and cell death.
c-Myc repression during development is crucial for the maturation of preacinar cells, and c-Myc overexpression can contribute to pancreatic carcinogenesis through the induction of a dedifferentiated state.
MYC negatively regulated the expression of genes involved in mitochondrial biogenesis and maintenance but positively regulated genes involved in DNA and histone methylation. Knockdown of MYC in colorectal cancer cells reset the altered metabolism and suppressed cell growth.
High myc expression is associated with Intestinal Tumorigenesis.
Methylparabens exposure increased malformations, LPO, apoptosis, ccnd1 and myca expressions, and decreased GST activities and NO levels compared with the control group.
Apoptosis was also observed with myca expression; introduction of homozygous tp53 (show TP53 Antibodies)(-/-) mutation into the myca transgenic fish reduced apoptosis and accelerated tumor progression.
MYC down-regulation induces mitochondrial apoptosis in T lymphoblasts.
These findings not only reveal a novel role of Mad1 (show MXD1 Antibodies) in regulating developmental cell death but also suggest that a balance of Mad and Myc controls cell fate determination during adult organ development.
Thyroid hormone (show PTH Antibodies) activates protein arginine methyltransferase 1 expression by directly inducing c-Myc transcription during Xenopus intestinal stem cell development.(
c-Myc has a direct role in the control of DNA replication
Findings support a model in which Myc, Twist and Slug/Snail2 function in a regulatory circuit within lateral plate mesoderm that directs normal vessel formation in both the vascular and lymphatic systems.
Expression of Drosophila Myc (dMyc) suppresses, whereas loss of dMyc enhances, ectopically activated JNK (show MAPK8 Antibodies) signaling-induced cell death. dMyc impedes physiologically activated JNK (show MAPK8 Antibodies) pathway-mediated cell death. Loss of dMyc triggers JNK (show MAPK8 Antibodies) pathway activation and JNK (show MAPK8 Antibodies)-dependent cell death.
tissue-specific downregulation of the Drosophila homolog of human c-myc proto-oncogene (dMyc) suppresses tau-mediated morphological and functional deficits by reducing abnormal tau hyperphosphorylation and restoring the heterochromatin loss.
dMyc has an essential role in preventing JNK (show MAPK8 Antibodies)-mediated retinal glial activation
the key target of the Psi/MED network in controlling developmentally regulated tissue growth is the transcription factor MYC.
Myc dosage plays crucial role in determining sex-specific size in Drosophila larvae and adult tissue. Double dose of Myc in females serves at least twice in development to promote sexual size dimorphism.
BicC (show BICC1 Antibodies) down regulates Myc in the Malpighian tubule.
activation of the TOR-Myc axis in midgut stem and progenitor cells influences a variety of traits in Drosophila
Drosophila adult muscle precursors display homing behavior to muscle niche and the niche-driven Insulin (show INS Antibodies)-Notch (show NOTCH1 Antibodies)-dMyc cascade plays a key role in setting the activated state of adult muscle precursors.
a functional link between Myc, a renowned oncogene (show RAB1A Antibodies), and the essential nucleotide biosynthetic enzyme CTPsyn.
MYC and S6K (show RPS6KB1 Antibodies) cooperate through coordinate activation of the essential Pol I transcription initiation factor TIF-1A (show RRN3 Antibodies).
The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene.
avian myelocytomatosis viral oncogene homolog
, class E basic helix-loop-helix protein 39
, myc proto-oncogene protein
, myc-related translation/localization regulatory factor
, proto-oncogene c-Myc
, transcription factor p64
, v-myc myelocytomatosis viral oncogene homolog
, c-myc proto-oncogene
, avian myelocytomatosis viral (v-myc) oncogene homolog
, Avian myelocytomatosis viral (v-myc) oncogene homolog
, myelocytomatosis viral oncogene homolog
, v-myc avian myelocytomatosis viral oncogene homolog
, cellular myelocytomatosis oncogene
, Proto-oncogene c-Myc
, Transcription factor p64
, transcriptional regulator Myc-A
, MYC II
, transcriptional regulator Myc-B
, Myc proto-oncogene protein
, CG10798 gene product from transcript CG10798-RB
, Diminutive protein
, lethal (1) G0354
, lethal (1) G0359